Lobbying disclosures · Lobbying report
MDGL: third_quarter 2026 lobbying report
Issues related to CMMI drug pricing; 340B drug pricing Most Favored Nation drug pricing; Issues related to CMMI drug pricing
Follow MDGL- Became public
- Oct 19, 2026, 3:46 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 9:29 AM EST
Why this is connected
Exact legal-name match: MADRIGAL PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/1157601/).
Reported lobbying amounts
Expenses: $350,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/0443ba02-ada5-4dde-bf54-d22892648069/","filing_uuid":"0443ba02-ada5-4dde-bf54-d22892648069","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/0443ba02-ada5-4dde-bf54-d22892648069/print/","filing_document_content_type":"text/html","income":null,"expenses":"350000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brooke Mahady","dt_posted":"2026-10-19T15:46:46-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1001 Conshohocken State Road","registrant_address_2":"Suite 2-350","registrant_different_address":true,"registrant_city":"West Conshohocken","registrant_state":"PA","registrant_zip":"19428","registrant":{"id":401109961,"url":"https://lda.gov/api/v1/registrants/401109961/","house_registrant_id":77230,"name":"MADRIGAL PHARMACEUTICALS, INC.","description":null,"address_1":"1001 Conshohocken State Road","address_2":"Suite 2-350","address_3":null,"address_4":null,"city":"West Conshohocken","state":"PA","state_display":"Pennsylvania","zip":"19428","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BROOKE MAHADY","contact_telephone":"+1 267-355-5512","dt_updated":"2026-10-15T16:16:58.765395-04:00"},"client":{"id":69058,"url":"https://lda.gov/api/v1/clients/69058/","client_id":69058,"name":"MADRIGAL PHARMACEUTICALS, INC.","general_description":"Biopharmaceutical company","client_government_entity":null,"client_self_select":true,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-09-08"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to CMMI drug pricing; 340B drug pricing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152916,"prefix":"ms","prefix_display":"MS.","first_name":"ANGELA","nickname":null,"middle_name":"WALKER","last_name":"RIEMER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Most Favored Nation drug pricing; Issues related to CMMI drug pricing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152916,"prefix":"ms","prefix_display":"MS.","first_name":"ANGELA","nickname":null,"middle_name":"WALKER","last_name":"RIEMER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in MDGL
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- May 19, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Madrigal Pharmaceuticals MDGL
$1K–$15K · Traded Apr 10, 2023 · disclosed May 19, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.